Predictions
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€48.17
18.12.20
18.12.20
€27.00
18.06.21
18.06.21
14.83%
19.01.21
19.01.21
Top 10 in its market
Good rating
Medium risks for its business
Bad culture
Pfizer Inc.
Start price
Target price
Perf. (%)
€31.01
18.12.20
18.12.20
€34.00
18.12.21
18.12.21
-5.35%
15.03.21
15.03.21
Small challenges to pay loans and raise capital
Innovative
Very small cyclical dependencies
Some uniques
Pfizer Inc.
Start price
Target price
Perf. (%)
€31.01
18.12.20
18.12.20
€34.00
18.12.21
18.12.21
-5.35%
15.03.21
15.03.21
Small challenges to pay loans and raise capital
Innovative
Very small cyclical dependencies
Some uniques
AstraZeneca plc
Start price
Target price
Perf. (%)
€83.36
18.12.20
18.12.20
€90.00
-3.42%
11.03.21
11.03.21
Could be worthwhile Investment >10% per year
Higher risks for its business
AstraZeneca plc
Start price
Target price
Perf. (%)
€83.36
18.12.20
18.12.20
€90.00
-3.42%
11.03.21
11.03.21
Could be worthwhile Investment >10% per year
Higher risks for its business
Pfizer Inc.
Start price
Target price
Perf. (%)
€30.91
17.12.20
17.12.20
€29.00
-1.81%
21.12.20
21.12.20
Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
Pfizer Inc.
Start price
Target price
Perf. (%)
€30.91
17.12.20
17.12.20
€29.00
-1.81%
21.12.20
21.12.20
Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
Catalyst Pharmaceutical Partners Inc
Start price
Target price
Perf. (%)
€3.06
13.12.20
13.12.20
-
13.12.21
13.12.21
1.50%
11.03.21
11.03.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Ionis Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€37.79
13.12.20
13.12.20
-
13.12.21
13.12.21
-29.55%
14.12.21
14.12.21
Risky Investment
Alexion Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€142.00
13.12.20
13.12.20
€170.00
13.12.21
13.12.21
9.00%
14.12.21
14.12.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Alexion Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€142.00
13.12.20
13.12.20
€170.00
13.12.21
13.12.21
9.00%
14.12.21
14.12.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Curis Inc.
Start price
Target price
Perf. (%)
€6.35
13.12.20
13.12.20
-
13.12.21
13.12.21
37.01%
16.02.21
16.02.21
Below average Marketposition
Probably not worthwhile Investment
Significant cyclical dependencies
Little known brand
Lexicon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.66
13.12.20
13.12.20
-
13.12.21
13.12.21
143.95%
16.02.21
16.02.21
Probably not worthwhile Investment
Significant cyclical dependencies
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€395.05
12.12.20
12.12.20
-
12.12.21
12.12.21
4.78%
09.01.21
09.01.21
Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€395.05
12.12.20
12.12.20
-
12.12.21
12.12.21
4.78%
09.01.21
09.01.21
Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€395.05
12.12.20
12.12.20
-
12.12.21
12.12.21
4.78%
09.01.21
09.01.21
Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
Pfizer Inc.
Start price
Target price
Perf. (%)
€35.01
12.12.20
12.12.20
-
12.12.21
12.12.21
-14.23%
24.03.21
24.03.21
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Could be worthwhile Investment >10% per year
Significant cyclical dependencies
Pfizer Inc.
Start price
Target price
Perf. (%)
€35.01
12.12.20
12.12.20
-
12.12.21
12.12.21
-14.23%
24.03.21
24.03.21
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Could be worthwhile Investment >10% per year
Significant cyclical dependencies
vTv Therapeutics Inc
Start price
Target price
Perf. (%)
€2.30
12.12.20
12.12.20
€1.00
12.12.21
12.12.21
-14.22%
26.06.21
26.06.21
Risky Investment
Revenue decline > 20% expected
EBIT decline > 20% expected
overvalued
aTyr Pharma Inc
Start price
Target price
Perf. (%)
€3.78
12.12.20
12.12.20
€2.00
12.12.21
12.12.21
4.76%
26.06.21
26.06.21
Risky Investment
Revenue decline > 20% expected
EBIT decline > 20% expected
Decining EBIT margin than peer group
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€392.75
11.12.20
11.12.20
€250.00
0.97%
11.12.20
11.12.20
Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market